Strong Innovation Recognition Aparito has been recognized as a finalist in the Innovation in STEM category and received the EURORDIS Company Award for Health Technology, highlighting its reputation for cutting-edge health tech solutions, which can be leveraged to position new product offerings.
Expanding Clinical Partnerships The company has formed collaborations with notable institutions such as the University of Birmingham and Raazi, demonstrating its active engagement in expanding digital health solutions across clinical research and low-income healthcare settings, opening avenues for partnerships or licensing opportunities.
Growth & Funding Profile With revenues between $1M and $10M and recent funding of $1.3M, Aparito shows promising growth potential in the digital health space, making it an attractive target for strategic investment, joint ventures, or technology licensing.
Technology-Driven Market Focus Aparito’s use of advanced tech stacks like Neo4j and cloud-based platforms for remote patient monitoring and digital trials positions it well to meet increasing demands for integrated digital health solutions in clinical and remote care markets.
Market Differentiation and Opportunities Recognized for its innovative approach in real-world data collection and patient-centric trials, Aparito offers sales opportunities in expanding telehealth, remote monitoring, and real-world evidence generation sectors driven by rising healthcare digitization trends.
Aparito - a wholly owned subsidiary of Eli Lilly and Company uses 8 technology products and services including RSS, Microsoft Access, Webpack, and more. Explore Aparito - a wholly owned subsidiary of Eli Lilly and Company's tech stack below.
| Aparito - a wholly owned subsidiary of Eli Lilly and Company Email Formats | Percentage |
| First.Last@aparito.com | 80% |
| First@aparito.com | 20% |
Hospitals and Health CareWales, United Kingdom11-50 Employees
Aparito’s mission is to digitise clinical trials and accelerate drug development for patients with life-limiting diseases by supporting patient-centric clinical trials. We do this through our Atom5™ eCOA platform using video assessments, wearable devices and ePROs to generate continuous real-world data.
Company Overview
Media & News
Funding & FinancialsAparito - a wholly owned subsidiary of Eli Lilly and Company has raised a total of $1.3M of funding over 4 rounds. Their latest funding round was raised on Mar 01, 2019 in the amount of $1.3M.
Aparito - a wholly owned subsidiary of Eli Lilly and Company's revenue is estimated to be in the range of $1M$10M
Funding & FinancialsAparito - a wholly owned subsidiary of Eli Lilly and Company has raised a total of $1.3M of funding over 4 rounds. Their latest funding round was raised on Mar 01, 2019 in the amount of $1.3M.
Aparito - a wholly owned subsidiary of Eli Lilly and Company's revenue is estimated to be in the range of $1M$10M
1-888-653-2347 
support@leadiq.com